Materialise NV

What they do

Materialise operates in 3D printing and additive manufacturing, combining software platforms with printing and medical device services. The filing references operating segments including Materialise Software, Materialise Medical, and Materialise Manufacturing. It generates revenue through software licenses, medical products, and manufacturing activities. The company reports under IFRS and files as a foreign private issuer with the SEC.

Revenue drivers

• Materialise Software — A reported operating segment that provides additive manufacturing software, with revenue recognized across goods and services transferred over time and at a point in time.
• Materialise Medical — A reported operating segment focused on medical applications, including the acquisition of technology-based and customer-related intangible assets from Feops NV in 2024.
• Materialise Manufacturing — A reported operating segment providing 3D printing and manufacturing services; the filing also references the Rapidfit NV disposal group held for sale.
• Geographic diversification — The filing discloses segment revenue by geography including Asia Pacific and Germany, indicating revenue is not concentrated in a single region.

Recent performance

The filing discloses revenue by segment and by timing of transfer, with amounts reported for goods or services transferred over time and at a point in time for the total segments. The company reported results for fiscal years 2025, 2024, and 2023, with comparative figures for trade receivables aging and property, plant and equipment. It also completed acquisitions including Feops NV (July 2024) and references RSPrint and AcTech in relation to technology-based and customer-related intangible assets. The filing includes a disposal group, Rapidfit NV, held for sale at fair value as of December 31, 2025. Specific revenue and net income figures were not provided in the excerpts available.

Strategy

Materialise is pursuing growth through acquisitions of technology and customer-related intangible assets, as shown by the Feops NV transaction completed on July 18, 2024. The company is consolidating its portfolio, evidenced by the Rapidfit NV disposal group held for sale. It continues to invest in software and medical segments, and maintains borrowing facilities including a KBC credit facility and bank loans. The company manages currency risk, with a focus on USD exposure. Its stated direction includes ongoing product development and geographic expansion.

Risks

• Customer concentration — The filing references a Zimmer Biomet agreement from May 2023, indicating potential dependence on a major customer.
• Currency risk — Materialise has disclosed currency risk exposure, particularly to the USD, which can affect reported results.
• Credit risk — The company monitors trade receivables aging, including amounts more than 181 days due, indicating exposure to customer payment defaults.
• Acquisition integration — Recent acquisitions such as Feops NV require integration of technology and customer relationships, which may not achieve expected benefits.

Outlook

The filing does not provide explicit forward-looking guidance. Management continues to focus on software, medical, and manufacturing segments while managing currency and credit risks. The company holds a disposal group for sale and may pursue further acquisitions. No specific revenue or earnings targets were disclosed in the available excerpts.